title: Continuous ST-segment monitoring associated with infarct size and left ventricular function in the GUSTO-I trial.
abstract: BACKGROUND
  The aim of this study was to evaluate whether in patients with myocardial infarction, the intensity and duration of myocardial ischemia as measured by continuous ST monitoring are associated with infarct size and residual left ventricular function.
  
  
  RESULTS
  The analyses included patients with myocardial infarction, receiving thrombolytic therapy, who were enrolled in the electrocardiographic substudy of GUSTO-I, monitored by a vector-derived 12-lead electrocardiographic recording system, and in whom either infarct size (defined as cumulative release of alpha-hydroxybutyrate dehydrogenase activity per liter of plasma over a 72-hour period [Q(72)]) or left ventricular ejection fraction (LVEF) was determined. With the use of linear regression analysis, we investigated the association of various ST-trend characteristics with Q(72) (206 patients) and with LVEF (180 patients). A higher area under the ST trend since thrombolysis until 50% ST recovery and a higher area under recurrent ischemic episodes (ST reelevations) were significantly associated with a higher Q(72), whereas only a higher area under recurrent ischemic episodes was significantly associated with a lower LVEF. These associations remained after adjusting for other patient characteristics such as age, sex, infarct location, and time to treatment.
  
  
  CONCLUSIONS
  These findings support the physiologic hypothesis that both the intensity and duration of myocardial ischemia (both reflected by the estimated areas under the ST-trend curve) determine myocardial damage and thus are associated with infarct size and ejection fraction in patients with acute myocardial infarction who receive thrombolytic therapy.
authors.affiliation: Julius Center for Patient Oriented Research, Utrecht University, The Netherlands.
authors.forename: K G
authors.initials: KG
authors.lastname: Moons
authors.forename: P
authors.initials: P
authors.lastname: Klootwijk
authors.forename: S H
authors.initials: SH
authors.lastname: Meij
authors.forename: G A
authors.initials: GA
authors.lastname: van Es
authors.forename: T
authors.initials: T
authors.lastname: Baardman
authors.forename: T
authors.initials: T
authors.lastname: Lenderink
authors.forename: M
authors.initials: M
authors.lastname: van den Brand
authors.forename: J D
authors.initials: JD
authors.lastname: Habbema
authors.forename: D E
authors.initials: DE
authors.lastname: Grobbee
authors.forename: M L
authors.initials: ML
authors.lastname: Simoons
mesh_terms: D000368:Aged; D004562:Electrocardiography / Q000592:standards*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000473:pathology*; D009206:Myocardium / Q000473:pathology*; D011379:Prognosis; D015912:Thrombolytic Therapy; D016277:Ventricular Function, Left